Navigation Links
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
Date:4/14/2008

BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA, data showing that commercial anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche), cetuximab (Erbitux(R); Bristol-Myers Squibb, Imclone, Merck Serono), and panitumumab (Vectibix(R); Amgen) can be converted to highly potent BiTE(R) antibodies (1). Likewise, the anti-IgE antibody omalizumab (Xolair(R); Genentech, Novartis) for the treatment of asthma can also be successfully converted into a BiTE antibody. BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against selected target cells, and represent a new therapeutic approach to therapy of cancer and other diseases.

All four BiTE antibodies were constructed using Micromet's novel proprietary BiTE platform that is fully human and cross-reactive with a wide variety of non-human primates. The presentation at AACR shows that all BiTE antibodies are active in eliminating cells expressing the respective target antigens of human and macaque origin. The four BiTE antibodies with specificity for EGFR, HER2/neu and IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml (18 picomolar).

"Our data show that commercially successful monoclonal antibody therapeutics can be converted into the T cell-engaging BiTE antibody format using our new BiTE platform," comments Patrick Baeuerle, chief scientific officer of Micromet. "With
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Changes in Management Team
4. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
11. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... December 25, 2014 The report “Stivarga ... focuses on the current treatment landscape, unmet needs, current ... Stivarga is a drug which is used in the ... orally administered and is also prescribed to patients who ... is FDA approved is a multi-kinase inhibitor and it ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... TUESDAY, Nov. 8 (HealthDay News) -- Despite concerns that the ... confuse older Americans, a new study finds seniors are able ... The researchers found evidence that seniors -- possibly with the ... as necessary. The findings may ease concerns among some ...
... Reporter , TUESDAY, Nov. 8 (HealthDay News) -- The latest ... might be better than other such scales at spotting people ... Columbia-Suicide Severity Rating Scale (C-SSRS) was developed eight years ago ... The new study, appearing online Nov. 8 in the ...
... What do Moby Dick, the Salem witch trials and alien ... sleep paralysis. Less than 8 percent of the general population ... groups -- students and psychiatric patients -- according to a ... of Pennsylvania. Sleep paralysis is defined as "a discrete period ...
... A team of Virginia Commonwealth University pediatric surgeons today successfully ... Tapia of the Dominican Republic. The complex, 20-hour ... surgery of its kind at the Children,s Hospital of Richmond ... in the VCU Department of Surgery and surgeon-in-chief, the team ...
... , PHILADELPHIA Thomas Jefferson University Hospital is ... to offer the recently-approved U.S. Food and Drug Administration ... BRAF mutation (which occurs in about half of all ... new, potentially life-saving drug. In August, the ...
... , TUESDAY, Nov. 8 (HealthDay News) -- Health care ... hands before and after treating their patients, new research shows. ... of Infection Control and Hospital Epidemiology , this lapse ... settings because some germs can get through latex gloves or ...
Cached Medicine News:Health News:Seniors Choose Medicare Prescription Plans Wisely: Study 2Health News:Suicide Checklist Spots People at Highest Risk 2Health News:Suicide Checklist Spots People at Highest Risk 3Health News:Psychologists chase down sleep demons 2Health News:VCU performs separation surgery on conjoined twins 2Health News:VCU performs separation surgery on conjoined twins 3Health News:Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
... brings to mind images of test tubes, vials, microscopes ... introduction of the Brady Code Reader 2.0 (CR2), you ... of critical lab tools. Brady Corporation has made bar ... with the introduction of the CR2. It is the ...
Reads single TrakMates tubes instantly, and drops decoded tube number instantly into any Windows application. System includes reader and Windows based software....
... top with powder-coated steel legs. ... Available in hundreds of sizes ... drawers, light fixtures and ionizing ... in custom building to meet ...
Medicine Products: